HealthAratus Intelligence

Cognoa

Cognoa
Cognoa Intelligence Room

Cognoa Intelligence

What the accumulated evidence, deployment record and lived experience actually show.

Intelligence lenses

Four ways of interrogating the same reality. Each changes the question, not the subject.

Do published findings about Cognoa match what happens in practice?

Still openWhether the reported magnitude holds in practice, and in which specialties it does not.

  • Public evidence

    Cognoa’s AI-based autism diagnosis aid gets FDA de novo clearance

    SignalHunt:validation:Cognoa

  • Public evidence

    Ability Center brings Cognoa's Canvas Dx to Saudi Arabia

    SignalHunt:validation:Cognoa

  • Public evidence

    FDA authorizes Cognoa autism spectrum disorder diagnostic aid

    SignalHunt:validation:Cognoa

  • Public evidence

    Cognoa Receives FDA Marketing Authorization for First-of-its-kind Autism Diagnosis Aid

    SignalHunt:validation:Cognoa

  • Public evidence

    Clinical Research

    SignalHunt:validation:Cognoa

What we know · what we don’t

Everything here is open to being corrected by someone who has seen it first-hand.

What we still don’t know

Nobody has answered these yet. Your experience can help us understand what is happening.

Unresolved

We still don’t know whether anyone at this organisation has actually used this technology — zero lived-experience observations exist.

Not yet answered

What are we missing?

Matters of record

Settled elsewhere. Context for reading the above, not something practice can confirm.

  • 70 public external signal(s) across 3 source(s).Recorded by HealthAratus

Tool intelligence

What HealthAratus understands

HealthAratus currently understands Cognoa through regulatory records, deployment evidence, company records and external market activity.

Category
imaging_diagnostics

What HealthAratus is still learning

HealthAratus is beginning to understand Cognoa. As evidence and experience accumulate, what remains unclear will be stated here.

Evidence & claims

What this is built on

The material the questions above were built from, with its attribution.

Canvas Dx is an AI-powered diagnostic tool for children aged 1.5 to 6 years. It assists clinicians by analyzing parent-provided videos and questionnaires to help identify autism spectrum disorder.According to Cognoa

What Cognoa states

The vendor’s own claims. Testable where practice can actually test them.

Stated capability

The tool uses machine learning to analyze parent-provided video and questionnaire data.

According to Cognoa

Does this change your workflow?

Independent and public evidence

Found in public sources. Not a clinician’s experience, and never presented as one.

Recent change

Ability Center brings Cognoa's Canvas Dx to Saudi Arabia

Reported publicly

Have you noticed this shift?

Recent change

Cognoa’s AI-based autism diagnosis aid gets FDA de novo clearance

Reported publicly

A matter of record — context, not something practice can confirm.

Recent change

FDA authorizes Cognoa autism spectrum disorder diagnostic aid

Reported publicly

A matter of record — context, not something practice can confirm.

Recent change

Cognoa Receives FDA Marketing Authorization for First-of-its-kind Autism Diagnosis Aid

Reported publicly

A matter of record — context, not something practice can confirm.

Company participation

Not yet verified

A record of the reality forming around this technology already exists. No representative of the company has verified participation yet.

Claim your company profile

Reference

The stable facts, for interpreting everything above.

Overview

What it does

• Product Overview: Cognoa offers Canvas Dx, an AI-powered diagnostic solution designed to assist clinicians in diagnosing or ruling out autism spectrum disorder (ASD) in children aged 1.5 to 6 years. (cognoa.com) • Technical Functionality: Canvas Dx utilizes machine…

Vendor & external product information, not independently verified by HealthAratus

Where it's used

Deployed in mixed settings, US

Key strength

Regulatory: FDA-authorized Class II diagnostic medical device, FDA Breakthrough Device Designation

Key capabilities

AI-driven autism diagnostic assessments, Remote evaluation via parent-submitted videos and questionnaires, Data-driven insights supporting clinical decision-making

Clinical use cases

Early autism diagnosis in pediatric clinics, Remote autism assessments for underserved communities, Accelerated referral processes for children with developmental concerns

Who uses it

Pediatricians, Child development specialists, Clinical psychologists

Parent Company
Cognoavendor
1 tracked tool

How the reality here has changed

Earlier activity concentrated on accuracy quality, adoption state, time saved. More recent activity concentrates on adoption state.

Earlier

  • accuracy quality
  • adoption state
  • time saved

More recently

  • adoption state

Connected intelligence